Evidence map›Paper›PMID 37622466›Full record

ReviewPigment cell & melanoma research2024

Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.

Inna Smalley, Adrienne Boire, Priscilla Brastianos, Harriet M Kluger, Eva Hernando-Monge, Peter A Forsyth, Kamran A Ahmed, Keiran S M Smalley, Sherise Ferguson, Michael A Davies and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pigment cell & melanoma research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Inna SmalleyDepartment of Metabolism and Physiology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0002-6796-9145
Adrienne BoireHuman Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Priscilla BrastianosDepartment of Medicine, MGH Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harriet M KlugerDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut, USA.
Eva Hernando-MongeDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Peter A ForsythDepartment of Neuro-Oncology and Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.ORCID 0000-0002-3756-8594
Kamran A AhmedDepartment of Radiation Oncology and Immunology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Keiran S M SmalleyDepartment of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0003-1089-9307
Sherise FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6344-0615
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-0977-0912
Isabella C Glitza OlivaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4530-7765
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USEastern Cooperative Oncology Group · USHarvard University · USMemorial Sloan Kettering Cancer Center · USYale Cancer Center · US

Funding

The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
Identification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2022
$3.5M
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, GERSTNER, ELIZABETH · 2020 to 2024
$3.4M
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasisR01CA256193 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI HARBOUR, JAMES WILLIAM, LICHT, JONATHAN D. · 2021 to 2025
$3.2M
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanomaR01CA262483 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Jonathan D. Licht, Keiran Smalley · 2022 to 2026
$2.4M
Developing new therapeutic strategies for brain metastasisR01CA277425 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando · 2023 to 2026
$2.2M
A Stepped-care Psychosocial Intervention for Brain Tumor Family CaregiversR01CA236034 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI BYRNE, MARGARET M, REBLIN, MAIJA · 2019 to 2023
$2.0M
Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy EscapeR00CA226679 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, INNA · 2020 to 2022
$747k
Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastasesR21CA274060 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, INNA · 2022 to 2023
$429k
Defining and targeting the epigenetic programs involved in melanoma developmentR21CA267141 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, KEIRAN · 2022 to 2023
$429k
Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastasesR21CA256289 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, KEIRAN · 2021 to 2022
$420k
Transplanting Unique Human Microbiomes to Improve Immunotherapy in GlioblastomaR21CA252634 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EGAN, KATHLEEN M., MCFARLAND, BRADEN COX · 2021 to 2021
$415k
Melanoma Research FoundationNCI NIH HHS P50 CA221703NCI NIH HHS R00 CA226679NCI NIH HHS R01 CA227156NCI NIH HHS R01 CA236034NCI NIH HHS R01 CA244975NCI NIH HHS R01 CA256193NCI NIH HHS R01 CA262483NCI NIH HHS R01 CA277425NCI NIH HHS R21 CA252634NCI NIH HHS R21 CA256289NCI NIH HHS R21 CA267141NCI NIH HHS R21 CA274060
6 · The paper itself

Abstract

Leptomeningeal disease (LMD) remains a major challenge in the clinical management of metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD continue to be excluded from almost all clinical trials. However, recent trials have demonstrated the feasibility of conducting prospective clinical trials in these patients. Further, new insights into the pathophysiology of LMD are identifying rational new therapeutic strategies. Here we present recent advances in the understanding of, and treatment options for, LMD from metastatic melanoma. We also annotate key areas of future focus to accelerate progress for this challenging but emerging field.

Indexed as

MelanomaRadiosurgeryHumansProspective StudiesCentral Nervous System Metastasisleptomeningeal diseasemelanoma

Identifiers

PMID37622466
PMCPMC12292448
OpenAlexW4386152826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.